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 Abstract 
A cross-sectional study  was carried out in Kirkuk city from December 2016 to March 
2017. The number of diabetic patients understudy were 180 whose ages were between 21-81 years 
old. These patients admitted to Kirkuk General Hospital and primary health care centers of Kirkuk 
first health care sector. The control group who were matched to the diabetic patients studied, 
included  90 healthy blood donors. Blood was collected for assessment of HbA1c test, blood 
glucose level, visfatin and chemerin levels. The study showed that the highest mean level of 
visfatin was found in diabetic patients comparing with healthy control ( 6.22±2.17 v.s. 3.54±1.91 
ng/ml). The study showed that the highest mean level of chemerin was found in diabetic patients 
comparing with healthy control (146.13±12.67 v.s. 92.17±8.01 ng/ml). The study showed that the 
highest mean level of visfatin was found in diabetic patients who have elevated level of glucose 
and HbA1c (5.75±3.81 and  5.91±3.67 ng/ml) respectively,  as compared with patients with 
normal level of glucose and HbA1c (4.61±2.99 and  3.95±2.12 ng/ml) respectively (P: ≤0.05). The 
study showed that the highest mean level of visfatin was found in diabetic patients who have 
elevated level of glucose and HbA1c (148.9±25.7 and  158.6±23.5 ng/ml) respectively,  as 
compared with patients with normal level of glucose and HbA1c (111.5±14.6 and  105.1±15.7 
ng/ml) respectively (P: ≤0.05),  Table 5 and 6.   
 It was concluded that There was a highly significant relation of visfatin and chemerin with type 2 
diabetes mellitus 
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Introduction  
Diabetes mellitus is a common metabolic disorder that is defined by chronic 
hyperglycemia. Besides symptoms related to hyperglycemia itself such as thirst, polyuria and 
weight loss, it may also cause potentially life-threatening acute hyperglycemic emergencies 
(1)
. It 
is a major cause of morbidity and premature mortality from long-term complications such as 
cardiovascular disease, blindness, renal failure, amputations and stroke. The types of diabetes have 
been classified by the WHO
(2)
.  Type 1 diabetes (previously referred to as insulin-dependent 
diabetes mellitus or IDDM) is due to absolute insulin deficiency and is usually an autoimmune 
disease leading to the destruction of the insulin-secreting beta cells in the pancreas. In some cases 
the cause of destruction of the beta cells is not known
(3)
. Type 2 (previously known as non-insulin 
dependent diabetes mellitus or NIDDM) results from relative insulin deficiency that may be 
associated with varying degrees of insulin action defects known collectively as insulin 
resistance
(4,5)
.  In the Arab world, it had been estimated that 11-20% of population had D.M 
especially in oil producing gulf countries
(6)
.   It has mentioned  that 10 % of Iraqi population had  
D.M. The first stage in type II diabetes is the condition called insulin resistance; although insulin 
can attach normally to receptors on liver and muscle cells, certain mechanisms prevent insulin 
from moving glucose into these cells where it can be used
(7,8)
.  Most type II diabetics produce 
variable, even normal or high, amounts of insulin, and in the beginning this amount is usually 
sufficient to overcome such resistance
(1)
.  Chemerin and visfatin are bioactive molecules that 
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regulate numerous physiological functions such as energy equilibrium, insulin action, 
inflammatory response and vascular homeostasis
(9)
.  In addition to its immunomodulatory effects, 
chemerin was reported to be associated with components of the metabolic syndrome and the 
parameters of type II diabetes including body massindex (BMI), plasma triglyceride (TG) levels, 
and blood pressure. Chemerin was shown to modulate the expression of adipocyte genes involved 
in glucose and lipid homeostasis
(10)
.  So the aim of  the study was to estimate the level of visfatin 
and chemerin in patients with type 2 diabetes. 
Material and method
A cross sectional study  was carried out in Kirkuk city from December 2016 to March 2017. The 
number of diabetic patients understudy were 180 whose ages were between 21-81 years old. These 
patients admitted to Kirkuk General Hospital and primary health care centers of Kirkuk first health 
care sector. The control group who were matched to the diabetic patients studied, included  90 
healthy blood donors. An interview was carried out with these  patients using questionnaire form 
designed by the investigator and consisted of the following variables; age, sex ,history of surgical 
operation and duration of diabetes. 
Five ml of blood was collected by vein puncture using Vacutainer tubes from each patient 
enrolled in this study. Blood samples were placed into two sterile test tubes, in one of them 2.5 ml 
of blood was put in test tube containing anticoagulant EDTA and used for assessment of HbA1c 
test using (immunefluorescent, ichroma, Korea). The second part of sample was 2.5 ml  was 
placed in plane tubes and centrifuged, the obtained sera were then aspirated and transferred into 
clean test tubes for estimation of blood glucose level (Biomerieux, France), visfatin and chemerin 
levels (Koma biotech, ELISA, USA). 
 Statistical analysis  
Computerized statistically analysis was performed using Mintab ver 18.0 statistic program. 
Comparison was carried out using Chi-square (X
2
) for determination of  the P. value. 
Findings 
The study showed that the highest mean level of visfatin was found in diabetic patients 
comparing with healthy control ( 6.22±2.17 v.s. 3.54±1.91 ng/ml) (P: ≤0.05).  
Table 1: Levels of visfatin in diabetic patients and the control group 
 
The study showed that the highest mean level of chemerin was found in diabetic patients 




Diabetic patients Control group P. value 
No. 180 90 
≤ 0.05 Mean 6.22 3.54 
SD 2.17 1.91 
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Table 2: Levels of chemerin in diabetic patients and the control group 
 
The study showed that the highest mean level of visfatin was found in diabetic patients 
who have elevated level of glucose and HbA1c (5.75±3.81 and  5.91±3.67 ng/ml) respectively,  as 
compared with patients with normal level of glucose and HbA1c (4.61±2.99 and  3.95±2.12 
ng/ml) respectively (P: ≤0.05),  Table 3 and 4.   
Table 3: Relation of  visfatin with glucose level in diabetic patients. 
Table 4: Relation of  chemerin with HbA1c level in diabetic patients. 
 
The study showed that the highest mean level of visfatin was found in diabetic patients 
who have elevated level of glucose and HbA1c (148.9±25.7 and  158.6±23.5 ng/ml) respectively,  
as compared with patients with normal level of glucose and HbA1c (111.5±14.6 and  105.1±15.7 
ng/ml) respectively (P: ≤0.05),  Table 5 and 6.   
Table 5: Relation of  chemerin with glucose level in diabetic patients. 
Chemerin level 
(ng/ml) 
Diabetic patients Control group P. value 
No. 180 90 
≤ 0.05 Mean 146.13 92.17 
SD 12.67 8.01 
visfatin  level 
(ng/ml) 
Blood glucose level 
P. value 
Normal   Elevated  
No. 40 140 
≤ 0.05 Mean 4.61 5.75 
SD 2.99 3.81 




Normal   Elevated  
No. 55 125 
≤ 0.05 Mean 3.95 5.91 
SD 2.12 3.67 
chemerin  level 
(ng/ml) 
Blood glucose level 
P. value 
Normal   Elevated  
No. 40 140 
≤ 0.05 Mean 111.5 148.9 
SD 14.6 25.7 
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Table 6: Relation of  chemerin with HbA1c level in diabetic patients. 
 
Discussion 
           Diabetic subjects had higher levels visfatin and chemerin compared to non-diabetic healthy 
blood donors. In addition, fasting plasma glucose and HbA1c were found to be independent 
determinants of visfatin.  
Berndt et al 
(11)
 found that there was a significant relation of visfatin and  type 2 diabetic 
regardless of their obesity. Consistent with our findings, Haider et al 
(12)
 showed that the release of 
visfatin by adipocytes in response to hyperglycaemia is dependent on the duration and extent of 
glucose elevation and is inhibited by insulin administration. It has been demonstrated that insulin 
does not influence visfatin synthesis in adipocytes and there is no difference in serum visfatin 
between type 2 diabetic subjects treated with insulin infusion or oral hypoglycaemic agents 
(12,13)
. 
Additionally, the influence of insulin sensitizing agents on serum visfatin level has not been 
confirmed yet 
(10)
. These findings suggest that fasting glucose levels, but not insulin resistance, 
may play a key role in the elevation of visfatin levels in newlydiagnosed type 2 diabetic patients. 
Additionally, we showed that along with fasting glucose, triglycerides is also directly and 





 found that Serum visfatin is highly associated with type 2 diabetes mellitus independent 
of insulin resistance and obesity. Result of Haddad et al 
(15)
   revealed that the T2DM group has 
the highest serum levels of chemerin compared to the control groups. Chang et al 
(16)
 revealed that 
plasma visfatin concentrations were increased in participants diagnosed with   type 2 diabetes 
mellitus when compared with healthy control and the highest level of this protein was found with 
elevated glucose level. Several clinical studies have analyzed the relationship between visfatin and 
insulin resistance, diabetes and obesity. However, these studies have provided disparate results 
(17-
19)
. In a meta-analysis, Berezin et al 
(20)
 suggested that the use of visfatin may predict increasing of 
HbA1c level in DM patients. In this study, we found increased visfatin levels in T2DM patients, 
as reported in previous studies 
(21)
.  El-Masallamy et al
(22) 
provided several explanations for the 
increased visfatin levels noted in patients with T2DM. Firstly, increased visfatin levels in diabetic 
patients may be due to impaired visfatin signaling in target tissues. Secondly, due to the insulin 
mimetic effects, increased plasma visfatin levels could be a compensatory mechanism in response 
to hyperglycemia that ameliorates the functional consequences of insulin deficiency or resistance. 
Thirdly, visfatin-mediated NAD biosynthesis that regulates glucose-stimulated insulin secretion 
may explain increased levels of visfatin in T2DM patients as a compensatory mechanism for β-
cell functioning. Finally, because of the pro-inflammatory properties, these elevated levels could 
be attributed to the chronic low-grade inflammation present in T2DM.  Several researches 
examined the association between serum chemerin concentrations in patients with T2DM 
(23-25)
. 
However, it is controversial whether chemerin is related to T2DM in humans. It has been shown 
that chemerin in 3T3-L1 adipocytes improves insulin stimulated glucose uptake through the 
insulin signaling. This suggested that chemerin may regulate insulin sensitivity of adipose 




Normal   Elevated  
No. 55 125 
≤ 0.05 Mean 105.1 158.6 
SD 15.7 23.5 
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, In that case with increase in chemerin concentration, the concentration of insulin should 
decline, but the experiment showed, FSI were positively correlated with serum chemerin. 
Conclusions: There was a highly significant relation of visfatin and chemerin with type 2 diabetes 
mellitus 
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